Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2019
Reporting Period: Second Quarter ended June 30, 2019
Context: The filing announces the financial results for the quarter ended June 30, 2019. The detailed results are contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text itself does not provide specific values for the following metrics:
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Guidance and Outlook: The text does not contain specific forward-looking guidance or management commentary regarding future performance.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt. The filing includes a standard disclaimer stating that the information is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability unless expressly incorporated by reference in other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 7, 2019) for actual revenue, net loss, and cash position figures.
- Verify the company's status as an Emerging Growth Company (indicated as "x" in the filing) and its election not to use the extended transition period for new accounting standards.
- Confirm the trading symbol OCUL on the Nasdaq Global Select Market.
- Check subsequent filings for any updates to the financial results announced in this 8-K.